WALTHAM, Mass. and BEVERLY HILLS, Calif., March 30, 2021 /PRNewswire/ — CorEvitas and The Guthy-Jackson Charitable Foundation (GJCF) are excited to announce plans for launching the SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions in NMOSD) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD). CorEvitas is the leading sponsor of registries in autoimmune and inflammatory diseases. In collaboration with GJCF, the SPHERES Registry is designed to better understand the benefit and safety of newly approved therapies for patients diagnosed with NMOSD…
Continue reading the press release.
SPHERES is a collaborative observational registry designed to collect real-world data on NMOSD patients to characterize the natural history of the disease, understand patterns of care, and explore clinical outcomes including effectiveness, patient experience, and safety events.
A standardized set of clinical outcome assessments will be collected from both patients and their treating neurologist at the time of enrollment and approximately every 6-months during the course of routine clinical care.
Target enrollment is approximately 800 NMOSD patients with no defined upper limit on enrollment. Approximately 35 clinical sites in the US and Canada will be recruited to participate. The registry is a long-term observational study. Sites will be compensated for their efforts.